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Elective orthopaedic cancellations due to 
the COVID-19 pandemic: where are we 
now, and where are we heading?
aims
The primary aim is to estimate the current and potential number of patients on NHS England 
orthopaedic elective waiting lists by November 2020. The secondary aims are to model re-
covery strategies; review the deficit of hip and knee arthroplasty from National Joint Registry 
(NJR) data; and assess the cost of returning to pre- COVID-19 waiting list numbers.
Methods
A model of referral, waiting list, and eventual surgery was created and calibrated using his-
torical data from NHS England (April 2017 to March 2020) and was used to investigate the 
possible consequences of unmet demand resulting from fewer patients entering the treat-
ment pathway and recovery strategies. NJR data were used to estimate the deficit of hip and 
knee arthroplasty by August 2020 and NHS tariff costs were used to calculate the financial 
burden.
results
By November 2020, the elective waiting list in England is predicted to be between 885,286 
and 1,028,733. If reduced hospital capacity is factored into the model, returning to full ca-
pacity by November, the waiting list could be as large as 1.4 million. With a 30% increase in 
productivity, it would take 20 months if there was no hidden burden of unreferred patients, 
and 48 months if there was a hidden burden, to return to pre- COVID-19 waiting list num-
bers. By August 2020, the estimated deficits of hip and knee arthroplasties from NJR data 
were 18,298 (44.8%) and 16,567 (38.6%), respectively, compared to the same time period 
in 2019. The cost to clear this black log would be £198,811,335.
Conclusion
There will be up to 1.4 million patients on elective orthopaedic waiting lists in England by 
November 2020, approximate three- times the pre- COVID-19 average. There are various 
strategies for recovery to return to pre- COVID-19 waiting list numbers reliant on increasing 
capacity, but these have substantial cost implications.
Cite this article: Bone Jt Open 2021;2-2:103–110.
Keywords: COVID-19, arthroplasty, economics, health policy
Introduction
The reorganization of hospital facilities to 
meet the COVID-19 challenge has necessi-
tated the cessation of routine elective ortho-
paedic surgery as resources are diverted to 
the frontline response.1,2 This mobilization 
of healthcare professionals and equipment 
avoided the dreaded scenario of the NHS 
becoming overwhelmed by COVID-19 cases, 
but this came at a cost borne by patients 
whose routine, yet necessary, elective proce-
dures were deferred.3 In addition to those 
already on waiting lists seeing their admis-
sion date put back, an increasing number of 
patients were failing to clear the first hurdle 
towards receiving definitive care by the 
reduction in access to primary care physi-
cians. This ‘silent’ waiting list of patients 
awaits a resumption of normal referral path-
ways before being entered or considered 
eligible to be placed onto elective waiting 
lists.
There has been a gradual return of elec-
tive orthopaedic services as the peak of 
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Fig. 1
Number of patients on elective trauma and orthopaedic waiting lists due to prior to the COVID-19 pandemic (March 2019).
table I. The predicted and actual number of patients on trauma and 
orthopaedic elective waiting lists according the month. The difference 
related to that predicted by the model and the actual number of patients 










Predicted 475,610 481,064 488,368 513,633
Actual 460,595 456,108 473,996 521,400
Difference 15,015 24,956 14,372 7,767
table II. Predicted number of patients on trauma and orthopaedic elective 
waiting lists according to the scenario and month.
Month (2020)



































COVID-19 pandemic has begun to fall.4,5 There is guid-
ance for which patients should go forward with surgery 
(i.e. those with the least potential risk of dying from 
COVID-19 should they contract it postoperatively), and 
measures that should be in place to reduce the risk of 
contracting COVID-19 in hospital.6 There are specific 
patient screening pathways to be followed.7 However, 
the capacity to deliver elective procedures continues to 
be constrained by the precautions necessary to do so in 
a safe setting.8,9
Planning elective surgery for the COVID-19 era requires 
a detailed appraisal of the amount of work waiting to be 
done; the likely rate of increase in the number of patients 
requiring surgery as services unlock; the increase in 
waiting times during the period of reduced activity; 
the resources necessary to bring waiting times back in 
line with the pre- COVID-19 performance. Previous work 
conducted by the COVIDsurg group estimated an 82% 
global cancellation rate during the peak 12 weeks of the 
COVID-19 pandemic.3 The cost of clearing this backlog 
in the UK was estimated at £2 billon, although this may 
underestimate the rate of cancellation in the UK where 
a complete shutdown was seen in many hospitals.3 
Furthermore, the COVIDsurg group assumed immediate 
return to 100% capacity after the 12- week period, which 
is currently not the case in elective orthopaedics.3
Knowledge of the current and accumulating backlog 
of elective hip and knee arthroplasty is an essential part 
of planning the recovery of services and return to pre- 
COVID-19 waiting times.2 These questions will be of 
relevance to all surgical specialities. Hip and knee arthro-
plasty procedures have previously shown stable levels 
of demand with predictable rates of increase.10 As such, 
and as the data for these common procedures are readily 
available in a reliable form, they were selected to model 
the work necessary to bring the provision of elective 
surgery back in line with pre- COVID-19 performance.
The primary aim of this study was to estimate the 
current and potential number of patients on trauma and 
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Fig. 2
Number of patients on elective trauma and orthopaedic waiting lists accounting for decreased capacity (August 70%, September 80%, October 90%) and 
return to full capacity by November 2020 (month 11: peak of the blue lines). The effect of the potential hidden demand (orange line) is also illustrated, and if 
there was a three- month delay in returning to 100% capacity (green and red lines) were also assesed.
orthopaedic elective waiting lists by November 2020. 
The secondary aims were to model recovery strategies, 
review the deficit of hip and knee arthroplasty, and assess 
the associated financial costs of recovery.
Methods
A model of the non- emergency orthopaedic trauma 
pathway was developed using the Python programming 
language to estimate the consequences of COVID-19 on 
patients referred for, or requiring, knee and hip arthro-
plasty. The model represents the pathway as a dynamic 
system, where patients are referred for treatment and 
spend time on a waiting list before being treated if they 
require surgery. The model allowed changes in either 
inflow (referrals) or outflow (eventual treatments) to be 
represented as effects on waiting list sizes and/or times 
while holding the proportion of patients referred who are 
suitable for surgery constant. The model incorporated 
seasonal differences in referrals and procedures:
 








where  Bt  is the waiting list at time  t ,  At  are referrals at time 
 t ,  Ot  are procedures carried out at time  t , and  ∂′t and  ∂′′t 
are constants that vary seasonally, taking 2019 values are 
best estimates of pre- COVID-19 seasonal variation.
In order to facilitate comparisons with previous time 
periods, the productivity coefficient (PC) was incorpo-
rated into the model: A PC of one represents a system in a 
state where patients progress along the pathway at histor-
ically average rates, assuming a constant rate of referrals 
and treatment capacity. A PC of 0.5 represents a doubling 
of the time on the waiting list, and a PC coefficient of 2 
represents a halving of time on the list; assuming inflows 
and treatment capacity are comparable. The model was 
calibrated using referrals to treatment (RTT) historic NHS 
waiting list data from England for 2019, matched by 
month and numbers of procedures in 2019 were used as 
a measure of treatment capacity.11
In order to model the unrealized/hidden demand’s 
effect of waiting lists, 2019 figures for May, June, and 
July were added to the April 2020 list and to the overall 
list estimated for December 2020. To model the implica-
tions of the plans to return to a normal PC by November, 
the increased size of the waiting list in December 2020 
was estimated based on the waiting list at April 2020. 
Finally, to estimate the resources, in terms of PC, required 
to return the waiting list to the levels expected pre- 
COVID-19 we estimated the months required to return to 
trend on varying PCs.
The model was developed using data from April 2017 
to March 2020 (separated into three time periods), using 
the number of new referrals, and number of in and 
outpatient treatments (Figure  1), which demonstrated 
high reliability with a R2 of 0.977. The model was a good 
fit with minimal over projection (1.5%) for August 2020 
(Table I).
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Fig. 3
Number of patients on elective trauma and orthopaedic (T&O) waiting lists according to level of productivity and time for no hidden demand (a) and a 
hidden demand (b). The baseline waiting list number at time zero was taken from the estimated burden of patients by November 2020 excluding hidden 
demand (0.8 million) and including hidden demand (1.4 million).
The number of elective total hip and knee arthro-
plasties performed for 2019 and 2020, up to August) 
were obtained from the National Joint Registry (NJR) of 
England, Wales, and Northern Ireland.12 This enabled a 
comparison of the number of arthroplasties that were 
performed in 2019 and 2020, to allow the deficit of proce-
dures due to diminished capacity due to the COVID-19 
pandemic. The National NHS tariff costs for hip (HB12B 
and HB12C) and knee (HB21B and HB21C) arthroplasty 
were used assign the cost for the estimated deficit in these 
procedures compared to same time period the year previ-
ously (January to August 2019) and the cost of increasing 
productivity to facilitate return to pre- COVIID-19 waiting 
list numbers.13 The cost for total hip arthroplasty was 
defined as £5,517, and £5,907 for total knee arthroplasty, 
which assumed 50% of the patients had a comorbidity 
that inflated the cost from baseline.
results
Primary aim: predicted t&O waiting listing burden by 
November 2020. By November 2020, the orthopaedic 
elective waiting list in England was predicted to be at least 
885,286 and at most 1,028,733, which was dependant on 
the case scenario of the hidden demand of patients that 
may present after the first wave of the COVID-19 pandemic 
(Table II). Whatever scenario was used it remained approx-
imately double the size of the pre- COVID-19 waiting list. If 
reduced hospital capacity was also factored into the model 
for August (70%), September (80%), October (90%) with 
return to full capacity (100%) by November, the number 
of patients on the waiting list could range from 0.8 million, 
if there was no hidden burden, to 1.4 million if there was a 
hidden burden (Figure 2). However, if there was a delay in 
returning to full capacity (to meet the demand) the num-
ber of patients waiting will increase and recovery to pre- 
COVID-19 waiting list numbers will take longer (Figure 2). 
If a delay in returning to full capacity of three months was 
modelled, from November 2020 to February 2020, this 
resulted in a four- month delay in return to pre- COVID-19 
waiting list numbers, due to the accrued increase in pa-
tients during those three months (Figure 2).
Secondary aims: recovery strategies. Time to recovery 
was directly proportional to the level of productivity and 
the number of patients on the waiting list, which was 
also dependent upon whether the hidden burden was 
accounted for or not (Figure 3). If the level of productivity 
were increased by 30%, it would take 20 months and 48 
months to return to pre- COVID-19 waiting list numbers if 
there was no hidden burden and with a hidden burden of 
patients, respectively.
Secondary aims: deficit of hip and knee arthroplasty and 
the associated financial costs of recovery. By August 2020, 
the estimated deficits in hip and knee arthroplasties per-
formed in 2020 compared to those performed January to 
August 2019 were 18,298 and 16,567, respectively. This 
represented a 44.8% fall in hip arthroplasty and 38.6% 
fall in knee arthroplasty compared to that same time pe-
riod in 2019 (Figure 4).
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Fig. 4
Number of hip and knee arthroplasty performed per month registered on the National Joint Registry.
Fig. 5
Cumulative costs of increasing the capacity of hip (A) and knee (B) arthroplasty according to the required level of activity and time using tariff data without 
any capital expenditure.
Using the NHS tariff cost for hip and knee arthro-
plasty, the cost to clear this black log alone would be 
£100,950,066 and £97,861,269, respectively. However, 
the cost may be far greater if capacity remained reduced 
and the number of patients waiting for their hip and knee 
arthroplasty increased. Increasing the productivity level 
to address this backlog is directly proportional to the 
incurred costs to undertake this (Figure 5). For example, 
working at an increase capacity of 30% compared to 
normal would cost approximately £200,000,000 to 
perform these additional hip and knee arthroplasties per 
year or £16,000,000 per month.
Discussion
This study has demonstrated that by November 2020 
the orthopaedic elective waiting list in England was 
predicted to be at least 885,286 and at most 1,028,733. 
If reduced hospital capacity were also factored into the 
model, with return to full capacity by November, the 
number of patients on the waiting list would be as high 
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as 1.4 million. If the level of productivity were increased 
by 30% compared to normal it would take 20 months 
if there was no hidden burden, and 46 months if there 
was, to return to pre- COVID-19 waiting list numbers. 
By August 2020, the estimated deficits in hip and knee 
arthroplasties in England, Wales, Northern Ireland, the 
Isle of Man, and the Channel Islands from NJR data were 
18,298 (44.8%) and 16,567 (38.6%), respectively. The 
cost to clear this black log alone would be £100,950,066 
and £97,861,269, respectively, but this does not account 
for the decreased capacity from August to November. 
Increasing the productivity level of hip and knee arthro-
plasty by 30% compared to normal would cost the NHS 
approximately £16,000,000 per month.
The major limitations of the current study are 
the assumptions made in predicting the burden of 
patients on the waiting list and for those waiting for 
a hip or knee arthroplasty. There will be a proportion 
of patients who will die while waiting or may choose 
to opt for private treatment due to the prolonged 
waiting times which would decrease the estimated 
burden of patients waiting presented in the current 
study. In contrast, there are factors that may result in 
an increased number of patients on the waiting list that 
were not included such as winter bed pressures, further 
waves of COVID-19 with cessation of elective services, 
and prolonged (beyond November 2020) reduced 
hospital capacity due to adherence to the new patient 
pathways.4 A further limitation of the current study 
is that only the backlog of hip and knee arthroplasty 
procedures and cost of addressing this were assessed. 
These procedures were chosen as they were thought 
to be representative, common elective orthopaedic 
procedures.10 These data also cover a different, larger 
geographical territory to the NHS England figures used 
for the activity modelling.
There is a further assumption that the proportion 
of referred patients who go on to receive surgery will 
remain constant, at around 50%. It is possible that the 
extra delay in referral, induced by difficulties in accessing 
hospital care during the pandemic, may lead to worse 
disease states by the time patients are assessed, with a 
greater proportion requiring surgical intervention.
This study offers the best available estimate of the 
current waiting list burden for elective orthopaedics 
in England and the potential backlog of hip and knee 
arthroplasty from the NJR. The COVIDSurg group esti-
mate of cancelations was not based on real data but on 
the estimated cancellation rate of the included experts 
across the globe at the end of March 2020.3 The preva-
lence of COVID-19 across the globe at that time varied 
and this estimated rate may not have been representa-
tive of the UK at that time.14 The current study has used 
real waiting list and NJR data gathered throughout the 
COVID-19 pandemic to estimate the number of patients 
and hip and knee arthroplasties that would have been 
observed compared to previous years.12 Furthermore, 
the COVIDSurg group assumed a 100% return to 
capacity after the pandemic (after 12 weeks),3 which is 
not the case currently due the restriction of new patient 
pathways and capacity of NHS healthcare facilities to 
deliver this, with most units working at 70% to 80% 
currently.4,8,15
The current study modelled this decreased capacity 
in the recovery phase from August 2020 to November 
2020 when capacity was assumed to return to 100%. 
However, these models did not account for a second 
wave with impact upon service capacity and winter 
bed pressures that may be greater this year because of 
COVID-19.
The delay to hip and knee arthroplasty may have 
an impact on the patient’s quality of life. Approxi-
mately 12% and 19% of patients waiting for hip and 
knee arthroplasty, respectively, are in a perceived 
“state worse than death” due to the functional deficit 
and pain from their joint disease.16 Scott et al16 high-
lighted that such patients are often prioritised by clini-
cians and undergo their surgery as soon as possible. 
However, these patients may have had their surgery 
delayed because of the COVID-19 pandemic and may 
not actually be offered surgery due to the criteria 
when restarting elective orthopaedic services, as frailer 
patients may be deemed too high of a mortality risk 
should they contract COVID-19 postoperatively and 
therefore may not be offered surgery.4,5
Several studies have shown that delaying hip and 
knee arthroplasty results in a worse preoperative func-
tional score which is subsequently associated with 
a worse postoperative health state17 and lower rate 
of patient satisfaction.18-20 The effect of the COVID-19 
pandemic on patient outcome will likely be difficult to 
quantify in the future, with patients living for longer 
with their disability and potentially having a worse 
outcome due to their delayed surgery.17,21 This should 
be assessed in future studies. Alternatively, some 
patients may not wish to go forward with their surgery 
when considering their increased mortality risk should 
they contract COVID-19 in the postoperative period.22 
At the height of the pandemic, the rate of cancellation 
was greater than 50%,22 but this has gradually declined 
to less than 5%,23 which may be related to the patients 
perceived risk of COVID-19 as the prevalence decreases.
The structure of the NHS elective service will likely 
be changed forever after this COVID-19 pandemic.4,6 
Measures that have been implemented to protect 
patients, such as social distancing within the hospital 
setting, will result in diminished capacity with the same 
amount of resources, such as ward capacity, relative to 
pre- COVID-19 levels. Actions to try and counteract this 
negative effect will need to be considered.4,6 A move 
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towards day case hip and knee arthroplasty may be one 
such action.24,25 It may be that the current facilities will 
not allow the NHS to regain the same capacity levels 
as pre- COVID-19 despite such interventions and more 
resources may need to be invested.
In addition to the cost of clearing the backlog, new 
costs may accrue associated with restructuring services 
and maintaining capacity while adhering to new stan-
dards. Returning to full capacity as soon as is safely 
possible must remain a priority: delaying this for three 
months results in a further delay of five months in 
returning to pre- COVID-19 waiting list numbers, as 
demonstrated by the current study.
It is not clear how the NHS protects elective ortho-
paedic service capacity in the coming months and years 
from further waves of COVID-19 infections and admis-
sions to acute hospital sites with the associated bed pres-
sures. Separating elective and acute services on different 
sites may be a way forward to ensuring continued 
capacity but this would come with a significant financial 
cost to the NHS.
There will be up to 1.4  million patients on elective 
orthopaedic waiting lists in England by November 2020. 
There are various options of recovery by increasing 
capacity to return to pre- COVID-19 waiting list numbers, 
but these have substantial cost implications on the NHS.
Take home message
  - Healthcare resources have been redirected from elective care 
towards dealing with the COVID-19 pandemic.
  - This redirection has resulted in a significant increase in the 
number of patients waiting for surgery.
  - Returning to pre- COVID-19 performance will require time and an 
increase in elective capacity.
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